Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $79.18M | $-64.72M | $-3.22 |
| 2024 | $70.01M | $9.95M | $0.50 |
| 2023 | $59.58M | $9.96M | $0.50 |
| 2022 | $53.91M | $12.48M | $0.62 |
| 2021 | $46.47M | $9.78M | $0.49 |
Social Signal Score
Earnings
Thu, Oct 29(in 2 months)
Consensus estimate $0.11 per share
Typical surprise +26.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 9$0.30 vs $0.23beat
- Thu, Apr 9$0.35 vs $0.27beat
- Thu, Jan 8$0.13 vs $0.18miss
- Mon, Dec 1$0.10 vs $0.10beat
- Mon, Jul 14$0.45 vs $0.26beat
- Thu, Apr 3$0.31 vs $0.25beat
Estimates and results for SLP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
SLPhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsbusinesswire.com·1d ago·Negative
…nces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the Company's previously announced acquisition by Altar…
View source ↗